We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravascular Laser Irradiation of Blood for Osteoarthritis of Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04598854
Recruitment Status : Unknown
Verified October 2020 by Liang-Cheng Chen, Tri-Service General Hospital.
Recruitment status was:  Not yet recruiting
First Posted : October 22, 2020
Last Update Posted : October 26, 2020
Sponsor:
Collaborator:
Ministry of Science and Technology, Taiwan
Information provided by (Responsible Party):
Liang-Cheng Chen, Tri-Service General Hospital

Brief Summary:
This research is designed through randomization, control, and double-blind trial to explore the clinical effectiveness of intravenous laser irradiation of blood for knee degenerative arthritis; and to explore the changes in body's balance function. Furthermore to establish a new way of clinical rehabilitation therapy. The research will further study the special biomarker to investigate the mechanism of low-energy intravenous laser therapy for osteoarthritis.

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Device: Intravascular laser irradiation of blood Device: Intravascular laser irradiation of blood (Sham) Not Applicable

Detailed Description:

Background This research is designed through randomization, control, and double-blind trial to explore the clinical effectiveness of intravenous laser irradiation of blood for knee degenerative arthritis; and to explore the changes in body's balance function. Furthermore to establish a new way of clinical rehabilitation therapy. The research will further study the special expression of blood cells after the treatment and as well as the molecular mechanism of low-energy intravenous laser therapy on hematopoietic stem cells. fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes. Pain control is indicated in such treatment, but still lacking evidence of improving the symptoms of degenerative knee arthritis.

Purpose This research is designed through randomization, control, and double-blind trial to explore the clinical effectiveness of intravenous laser irradiation of blood for knee degenerative arthritis; and to explore the changes in body's balance function. Furthermore to establish a new way of clinical rehabilitation therapy. The research will further study the special biomarker to investigate the mechanism of low-energy intravenous laser therapy for osteoarthritis.

Method The investigators plan to recruit 20 patients who are between the ages of 50 to 75 years old, but younger than 75 years old. The participants are required to have clear conscious and be able to communicate. Their symptoms of degenerative arthritis could be one or both knees which last more than six months; with knee pain greater than 4 points when walking. The treatment group will receive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity. This plan will be explained to the patient in detail during the outpatient visit and patients will sign the consent form upon agreement. Before intravenous laser irradiation, three days, one month, and three months after the therapy, 20 ml of autologous peripheral venous blood need to be drawn for basic blood tests and biomarker tests. At the same time, the clinical functions of patients will be evaluated, including visual analogous scale, Lequesne 's severity index, WOMAC scale, and balance function test.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The treatment group will receive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Investigation of Therapeutic Effect and Molecular Mechanism After Intravascular Laser Irradiation of Blood for Osteoarthritis of Knee
Estimated Study Start Date : October 2020
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Treatment group
The treatment groupreceive an intravenous helium-neon laser phototherapy. A vein indwelling needle will be placed in their veins located in the upper elbow, and the laser fiber catheter will be introduced through the indwelling cannula. The power is set between 2.5 ~ 3.0Mw, 60 minutes each time, once a day for five consecutive days. The steps for the control group are the same, except that the output power is adjusted to zero intensity.
Device: Intravascular laser irradiation of blood
Low intensity intravascular laser irradiation of blood phototherapy is a method of a 632.8 nm red light penetrate into a vein through fiber and the brightness is 100 fold of the sun. The light accelerates blood and cells circulation in the human body, so that protein molecular structure would promote changes.

Sham Comparator: Control group
The steps for the control group are the same as the treatment group, except that the output power is adjusted to zero intensity.
Device: Intravascular laser irradiation of blood (Sham)
zero intensity of the laser energy




Primary Outcome Measures :
  1. Visual Analogue Scale (VAS) of the degree of pain [ Time Frame: 3 months ]
    with the score ranging from 10 (tremendous pain) to 0 (no pain). Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  2. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) [ Time Frame: 3 months ]
    Score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The higher score means more severity. Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  3. Lequesne 's severity index [ Time Frame: 3 months ]
    Three domain: pain or discomfort, maximum distance walked, activities of daily living. Score range of 0-26. The higher score means more severity. Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  4. Balance function test [ Time Frame: 3 months ]
    Test standing balance,including static, dynamic with opening and closing eyes, and single leg stance. Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.


Secondary Outcome Measures :
  1. Serum Interleukin 6 (IL6) [ Time Frame: 3 months ]
    chemiluminescent enzyme immunometric assay method. Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  2. Serum cartilage oligomeric matrix protein (COMP) [ Time Frame: 3 months ]
    immunoassay ELISA. Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  3. Serum procollagen type II N-terminal propeptide (PIIANP) [ Time Frame: 3 months ]
    ELISA. Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  4. Serum calcitonin gene-related peptide (CGRP) [ Time Frame: 3 months ]
    immunosorbent assay (ELISA). Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  5. Substance P [ Time Frame: 3 months ]
    Substance P Immunoassay Test. Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.

  6. The number of synovium-derived stem cell with CD73, CD90, CD105 [ Time Frame: 3 months ]
    flow cytometry, Measure before intravenous laser irradiation, three days, one month, and three months after the therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clear conscious and be able to communicate.
  • the symptoms of degenerative arthritis could be one or both knees which last more than six months
  • with knee pain greater than 4 points when walking

Exclusion Criteria:

  • had ever received intraarticular injection with hyaluronic acid or steroid within 6 months
  • had ever received nonsteroidal anti-inflammatory drugs or steroid therapy within 1 week
  • neoplasm of joint and peripheral soft tissue
  • malignancy
  • had ever received total knee arthroplasty or other major surgery
  • rheumatoid arthritis
  • coagulopathy
  • unable to take balance test due to other chronic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04598854


Contacts
Layout table for location contacts
Contact: Liang-Cheng Chen, MD,MS 886-2-87923311 ext 17068 clctsgh@yahoo.com.tw

Sponsors and Collaborators
Tri-Service General Hospital
Ministry of Science and Technology, Taiwan
Investigators
Layout table for investigator information
Principal Investigator: Liang-Cheng Chen, MD,MS Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital
Publications:
Layout table for additonal information
Responsible Party: Liang-Cheng Chen, Clinical Professor of Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital
ClinicalTrials.gov Identifier: NCT04598854    
Other Study ID Numbers: 109WFE0110237
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: October 26, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Liang-Cheng Chen, Tri-Service General Hospital:
Intravascular laser irradiation of blood
Osteoarthritis, Knee
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases